Delivery Order SPE2DB24D1006-SPE2DB25FCFDJ
- Not listed
- The Defense Logistics Agency awarded a $1,803.20 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for NovoLog 100 Unit/mL vials (10 mL units). This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a $2,737.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of NovoLog 100 Unit/mL vials (10mL). The contract, which is a child order under a larger indefinite delivery contract, carries an ultimate completion date of August 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a non-competitive, competitively awarded transaction...
- The Defense Logistics Agency awarded a $1,944.90 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10 mL) on July 18, 2025, with completion scheduled for July 21, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor specializing in medical supply chain support for military and veteran healthcare...
- The Defense Logistics Agency awarded a $6,193.54 firm fixed-price delivery order to AmerisourceBergen Drug Corp on May 6, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) to support federal medical procurement needs. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $1,944.90 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) with a firm fixed price structure and completion date of September 15, 2025. This is an unset-aside, competitively awarded contract issued on September 12, 2025, with performance to be completed at the vendor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $1,040.41. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 29, 2025. This delivery order represents...
- The Defense Logistics Agency awarded a $1,296.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp on April 23, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL). This is a non-set-aside contract with an ultimate completion date of April 24, 2025, and represents a child delivery order under a larger contract vehicle. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin used in diabetes management,...
- The Defense Logistics Agency awarded a $7,312.25 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL). This is a firm fixed price, non-set-aside contract with a completion date of July 30, 2025, and represents a child order under AmerisourceBergen's larger pharmaceutical supply framework with DLA. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office and serves as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,761.94 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on June 16, 2025, with an ultimate completion date of June 17, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $4,819.02 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL). The contract, classified as a firm fixed price delivery order with an ultimate completion date of August 18, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation. This delivery order is issued...
- SPE2DB24D1006Indefinite Delivery Contract
- SPE2DB24D1006-SPE2DB25FCFDJDelivery Order
The Defense Logistics Agency awarded a $1,296.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL units). The contract, which is not set-aside and competitively awarded, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. Performance will be completed by September 18, 2025, with the pharmaceutical product being delivered to Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The NovoLog insulin product supports diabetes management within the Defense Health Agency and broader military healthcare programs. This delivery order exemplifies the company's extensive portfolio of pharmaceutical supply contracts with the DLA, which encompasses a comprehensive range of medications, vaccines, and medical supplies across multiple therapeutic domains, demonstrating the vendor's capability to fulfill specialized federal medical supply requirements through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 9/17/25 |